Evidence map›Paper›PMID 35841068›Full record

ArticleBiology of sex differences2022

The effect of nicotine-containing products and fetal sex on placenta-associated circulating midpregnancy biomarkers.

Birgitte Kordt Sundet, Ina Kreyberg, Anne Cathrine Staff, Karin Cecilie Lødrup Carlsen, Karen Eline Stensby Bains, Jens Petter Berg, Berit Granum, Guttorm Haugen, Gunilla Hedlin, Christine Monceyron Jonassen and 10 more

Open access · goldAbstract read
In one paragraph

Article in Biology of sex differences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Research progress on the effects of adverse exposure during pregnancy on skeletal muscle function in the offspring.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 2 countries.

Birgitte Kordt Sundet *Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Ina Kreyberg *Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Anne Cathrine StaffFaculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Karin Cecilie Lødrup CarlsenFaculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Karen Eline Stensby BainsFaculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Jens Petter BergFaculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Berit GranumDepartment of Environmental Health, Norwegian Institute of Public Health, Oslo, Norway.
Guttorm HaugenFaculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Gunilla HedlinAstrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
Christine Monceyron JonassenFaculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.
Live Solveig NordhagenDivision of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
Björn NordlundAstrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
Eva Maria RehbinderFaculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Knut RudiFaculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.
Corina Silvia RueeggOslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway.
Katrine Dønvold SjøborgDepartment of Obstetrics and Gynecology, Østfold Hospital Trust, Kalnes, Norway.
Håvard Ove SkjervenFaculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Cilla SöderhällAstrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
Riyas VettukattilFaculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Meryam SugulleFaculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. uxsume@ous-hf.no.ORCID 0000-0003-4160-3978
Oslo University Hospital · NOKarolinska University Hospital · SEØstfold Hospital Trust · NONorwegian Institute of Public Health · NONorwegian University of Life Sciences · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn utero exposure to nicotine, largely assessed by smoking, is a risk factor for impaired offspring health, while potential effects of non-combustible nicotine use such as snus (oral moist tobacco), are less well-known. Maternal serum concentrations of placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) may be viewed as "placenta health markers", known to differ by fetal sex. Maternal smoking during pregnancy has been associated with lower levels of circulating sFlt-1, while the effect of snus on placenta-associated angiogenic factors is unknown. Our aim was to explore if snus and/or smoking exposure was associated with midpregnancy maternal levels of sFlt-1, PlGF and sFlt-1/PlGF ratio if these associations were modified by fetal sex.

methodsMidpregnancy (16-22 gestational weeks) serum from 2603 Scandinavian women enrolled in the population-based multi-center PreventADALL (Preventing Atopic Dermatitis and ALLergies in children) study was analysed for sFlt-1 and PlGF concentrations by electrochemiluminescence, deriving the sFlt-1/PGF ratio. Nicotine use was assessed by electronic questionnaires at enrollment in 2278 of the women. Univariable and multivariable linear regression models on log transformed outcomes were used to assess the association between nicotine use and biomarker levels. Interaction terms were included to identify whether the associations were modified by fetal sex.

resultsMedian sFlt-1, PlGF and sFlt-1/PlGF ratios among women with nicotine exposure information were similar to those of all included women and differed by fetal sex. Current snus use was significantly associated with reduced maternal circulating PlGF levels in adjusted analyses [β - 0.12, (95% CI - 0.20; 0.00) compared to never use, p = 0.020]. A significant interaction between fetal sex and snus exposure was observed for PIGF (p = 0.031). Prior or periconceptional snus use was significantly associated with PIGF in male fetus pregnancies [β - 0.05 (95% CI - 0.09 to (- 0.02)) and β - 0.07 (95% CI - 0.12 to (- 0.02)) compared to never use, p = 0.002]. Smoking was not significantly associated with any circulating biomarkers levels.

conclusionsMidpregnancy maternal angiogenic profile differed by periconceptional snus use and fetal sex. Snus exposure, perceived as "safe" by users, before or during pregnancy seems to affect midpregnancy placental health in a sex dimorphic manner.

Indexed as

NicotineVascular Endothelial Growth Factor Receptor-1BiomarkersChildFemaleHumansMalePlacentaPlacenta Growth FactorPregnancyBiomarkersNicotinePlacenta Growth FactorVascular Endothelial Growth Factor Receptor-1Angiogenic proteinsFetal sexMoist tobaccoNicotinePlacentaPreventADALL

Identifiers

PMID35841068
PMCPMC9284818
OpenAlexW4285590050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.